Biomerica (BMRA) vs Q/C Technologies (QCLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biomerica is the larger company by market cap ($8.4 million vs $5.2 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRA | QCLS |
|---|---|---|
| Share price | $1.84 | $0.63 |
| Market cap | $8.44M | $5.16M |
| 1-day change | -1.86% | -1.05% |
| YTD return | -25.00% | — |
| 1-year return | -34.38% | — |
| 5-year return | -95.74% | — |
| P/E ratio (TTM) | — | 0.24 |
| Forward P/E | 4.71 | — |
| EPS (TTM) | $-1.30 | $2.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.21 | $8.17 |
| 52-week low | $1.45 | $0.42 |
| Distance from 52-week high | -42.83% | -92.29% |
| Average volume | 70.88K | 4.98M |
| Shares outstanding | 4.60M | 8.19M |
| Employees | 50 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biomerica
BMRA stock →Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 50 employees
About Q/C Technologies
QCLS stock →Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 3 employees
BMRA vs QCLS FAQ
Which is bigger, Biomerica or Q/C Technologies?
Biomerica (BMRA) is larger, with a market capitalization of $8.44M compared with $5.16M for Q/C Technologies (QCLS).
Are Biomerica and Q/C Technologies in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.